Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNYSE:BFLYNASDAQ:LNSRNASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$12.11-2.1%$12.53$11.84▼$25.36$560.02M1.14512,584 shs282,530 shsBFLYButterfly Network$2.30-5.9%$2.35$0.82▼$4.98$567.53M2.543.06 million shs2.90 million shsLNSRLENSAR$12.50$13.69$3.50▼$17.31$147.40M0.5282,229 shs57,825 shsRXSTRxSight$14.21-0.4%$14.87$12.53▼$60.81$577.45M1.29704,200 shs535,197 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical+0.13%+0.02%-3.22%-14.60%-38.88%BFLYButterfly Network-2.98%+3.61%+2.52%-8.79%+151.99%LNSRLENSAR-3.55%-4.29%-10.65%-17.38%+156.15%RXSTRxSight-4.29%-4.36%+8.11%-44.78%-75.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAvanos Medical1.7561 of 5 stars0.03.00.00.01.31.72.5BFLYButterfly Network2.2716 of 5 stars3.51.00.00.02.32.50.6LNSRLENSAR1.4295 of 5 stars2.03.00.00.02.82.50.0RXSTRxSight3.0683 of 5 stars4.22.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAvanos Medical 0.00N/AN/AN/ABFLYButterfly Network 3.00Buy$4.0074.29% UpsideLNSRLENSAR 2.00Hold$15.0020.00% UpsideRXSTRxSight 2.30Hold$37.90166.71% UpsideCurrent Analyst Ratings BreakdownLatest LNSR, BFLY, RXST, and AVNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/5/2025BFLYButterfly NetworkLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.003/24/2025LNSRLENSARBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025LNSRLENSARLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$16.00 ➝ $15.003/21/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $36.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAvanos Medical$689.20M0.81$1.59 per share7.64$26.63 per share0.45BFLYButterfly Network$85.63M6.63N/AN/A$1.06 per share2.17LNSRLENSAR$57.07M2.58N/AN/A$2.97 per share4.21RXSTRxSight$148.31M3.89N/AN/A$4.47 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAvanos Medical-$61.80M-$8.3735.627.00N/A2.30%4.70%3.46%7/30/2025 (Estimated)BFLYButterfly Network-$133.70M-$0.29N/AN/AN/A-129.25%-42.68%-30.31%8/7/2025 (Estimated)LNSRLENSAR-$14.38M-$4.85N/A∞N/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)Latest LNSR, BFLY, RXST, and AVNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/6/2025Q1 2025AVNSAvanos Medical$0.19$0.26+$0.07$0.14$161.75 million$167.50 million5/2/2025Q1 2025BFLYButterfly Network-$0.09-$0.06+$0.03-$0.06$21.16 million$21.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAvanos MedicalN/AN/AN/AN/AN/ABFLYButterfly NetworkN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAvanos Medical0.122.221.46BFLYButterfly NetworkN/A4.662.95LNSRLENSARN/A3.372.10RXSTRxSightN/A12.6711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAvanos Medical95.17%BFLYButterfly Network37.85%LNSRLENSAR40.15%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipAVNSAvanos Medical2.64%BFLYButterfly Network25.18%LNSRLENSAR38.52%RXSTRxSight9.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAvanos Medical4,04046.24 million44.15 millionOptionableBFLYButterfly Network460247.29 million154.94 millionOptionableLNSRLENSAR11011.79 million7.14 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableLNSR, BFLY, RXST, and AVNS HeadlinesRecent News About These CompaniesRxSight (NASDAQ:RXST) Trading Down 5.6% - Here's WhyJune 11 at 4:42 PM | marketbeat.comRxSight: Valuation Blowout Creates OpportunityJune 7, 2025 | seekingalpha.comRxSight (NASDAQ:RXST) Stock Price Down 5.5% - What's Next?May 31, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Nuveen Asset Management LLCMay 31, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Investments LPMay 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 46,700 RxSight, Inc. (NASDAQ:RXST)May 28, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by D. E. Shaw & Co. Inc.May 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 74,800 Shares of RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRoyal Bank of Canada Raises Holdings in RxSight, Inc. (NASDAQ:RXST)May 27, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Voloridge Investment Management LLCMay 26, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?May 25, 2025 | marketbeat.comTwinbeech Capital LP Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 25, 2025 | marketbeat.comDo Options Traders Know Something About RxSight Stock We Don't?May 23, 2025 | msn.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Hold" by BrokeragesMay 23, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Invests $2.99 Million in RxSight, Inc. (NASDAQ:RXST)May 22, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Upgraded to Overweight at Wells Fargo & CompanyMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 21, 2025 | marketbeat.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comPolar Asset Management Partners Inc. Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Purchases 39,347 Shares of RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNSR, BFLY, RXST, and AVNS Company DescriptionsAvanos Medical NYSE:AVNS$12.11 -0.26 (-2.10%) Closing price 03:59 PM EasternExtended Trading$12.11 0.00 (0.00%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Butterfly Network NYSE:BFLY$2.30 -0.15 (-5.94%) Closing price 03:59 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.LENSAR NASDAQ:LNSR$12.52 +0.02 (+0.16%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.RxSight NASDAQ:RXST$14.21 -0.06 (-0.42%) Closing price 04:00 PM EasternExtended Trading$14.20 -0.01 (-0.04%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
